Phase1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX2-73
- ANAVEX® Life Sciences Corp.
- Dec 11, 2014
- 1 min read
Updated: Sep 7, 2022
CNS Summit 2014, Boca Raton, FL
Ole Voges, Ingo Weigmann, Norman Bitterlich, Christoph Schindler and Christopher Missling
